Roche Cancer Drug Meets Study Goal
Posted on: Monday, 11 December 2006, 12:01 CST
Roche has said a phase III study of Xeloda in patients with advanced colorectal cancer met its primary endpoint of progression-free survival, showing it to be as effective as standard medication.
The primary objective was to answer whether the Xelox (oral Xeloda plus oxaliplatin) regimen is as effective as Folfox-4 (infused 5-FU/leucovorin plus oxaliplatin) in delaying disease progression or death. The secondary outcomes, to be reviewed included overall survival, overall response rates and safety profile.
Study results showed that the chemotherapy combination Xelox is as effective in delaying disease progression as the chemotherapy combination Folfox-4 in previously untreated colorectal cancer patients.
"By demonstrating that Xeloda in combination with oxaliplatin was as effective as Folfox-4, these two studies provide the strongest evidence yet that Xeloda may be used in place of IV 5-FU in the treatment of patients with advanced colorectal cancer," said Mace Rothenberg, professor of medicine at Vanderbilt University Medical Center.
Xeloda is an oral chemotherapy that can be taken at home and has an important convenience benefit for both patients and doctors compared to intravenous infusions which require multiple hospital visits. Xeloda is already used in previously untreated colorectal cancer patients and last year it received the additional approval for the treatment of early colon cancer.
Source: Datamonitor
Related Articles
- Depression In Older Cancer Patients Can Be Effectively Treated With Collaborative Approach
- Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
- Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
- Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
- Study Suggests Survival Benefit From Radioactive Microsphere Therapy in Patients With Colorectal Cancer Liver Metastases Who Have Failed Chemotherapy
- Oral Colon Cancer Drug Effective
- Medivation Cancer Drug Effective in Preclinical Studies
- Genta Cancer Drug Effective in Triple Combination
- FDA Approves Vectibix for Patients With Colorectal Cancer
- Two Studies Demonstrate Significant Benefit of ELOXATIN-Based Chemotherapy Combined With Bevacizumab in Advanced Colorectal Cancer
 |
 |
User Comments (0)
RSS Feeds